Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
The split will reduce outstanding shares from 4.77 million to approximately 1.59 million.
Reverse Stock Split
Entero Therapeutics, Inc. is implementing a 1 for 3 reverse stock split to maintain Nasdaq listing compliance.
Share Consolidation
Every 3 shares will be combined into 1 share, reducing outstanding shares to approximately 1.59 million.
Fractional Shares
Stockholders entitled to fractional shares will receive cash in lieu of fractional shares.
- The reverse stock split aims to enhance shareholder value by maintaining a Nasdaq listing.
- Reducing outstanding shares can lead to increased visibility and credibility in the market.
The reverse stock split demonstrates Entero Therapeutics, Inc.'s commitment to meeting Nasdaq requirements and enhancing shareholder value in the biopharmaceutical sector.